Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15435832 | 0.75 | PARP15 (0.42) | HTTPARP1RENPARP15PARP10 | |
| SCHEMBL15417907 | 0.73 | REN (0.54) | REN | |
| SCHEMBL8284765 | 0.68 | LMNA (0.43) | HTTPARP1RENMEN1NR1I2 | |
| SCHEMBL27492782 | 0.68 | KMT2A (0.49) | HTTMEN1NR1I2LMNACHRM2 | |
| SCHEMBL12526584 | 0.67 | REN (0.50) | REN | |
| SCHEMBL3612957 | 0.66 | LMNA (0.69) | HTTPARP1MEN1NR1I2LMNA | |
| SCHEMBL15417928 | 0.65 | HSP90AA1 (0.39) | HTTGPR88RENMAPTALDH1A1 | |
| SCHEMBL12524628 | 0.65 | PARP10 (0.41) | HTTPARP1MEN1NR1I2LMNA | |
| SCHEMBL12524635 | 0.65 | ROCK2 (0.39) | GPR88RENKDM4E | |
| SCHEMBL6043409 | 0.63 | MAPK1 (0.48) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155731-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-12-18 | — | — | US | disclosed |
| EP-2933248-B1 | NOVEL RENIN INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-2687518-B1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-9278944-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| EP-2933248-A1 | NOVEL RENIN INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| EP-2687518-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | HTT 2755/4885GPR88 1232/4885PARP1 4607/4885 |
| US-10155731-B2 | Nitrogen-containing saturated heterocyclic compound | REN, AGTR1, AGTR2 | HTT 2755/4885GPR88 1232/4885PARP1 4607/4885 |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | HTT 3051/4885GPR88 708/4885PARP1 4109/4885 |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | HTT 2755/4885GPR88 1232/4885PARP1 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.